Cette équipe de biologistes et endocrinologues du Brigham and Women's Hospital (BWH, Boston) révèle toute l’importance de ...

" Nous ne vivons plus plus longtemps ", conclut cette équipe d’épidémiologistes de l’Université d'East Anglia (UEA, Angleterre). L’analyse, publiée dans le Lancet Public Health, révèle en effet un ral ...

renforcer la compétitivité et la capacité de production des médicaments essentiels en Europe grâce à des mécanismes de ...

Title: Impact of the Enzyme Replacement Therapy, INZ-701, in Children with ENPP1 Deficiency: Experience from an Expanded Access Program Presentation Number: 10 – Poster Session Date: Saturday, ...

LONDON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage clinical company developing lifesaving treatments for advanced liver diseases, announced today the appointment of a series of ...

The proceeds from the exercise of the warrants will be used for general working capital purposes, including Firefly’s recently announced strategic initiative to build the world’s first foundation ...

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference ...

Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the ...

WEST VALLEY CITY, Utah, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company committed to bringing supply stability and innovation to radioisotope markets, was named “Researcher of the Year” at ...

Ivor Elrifi, CEO of Tiziana Life Sciences, commented, “Partnering with Renaissance is a significant milestone in our mission to bring intranasal foralumab to patients in need. Their proven track ...

Seer’s management is scheduled to participate in a fireside chat on Tuesday, March 4 th at 11:50 a.m. Eastern Time / 8:50 a.m. Pacific Time. A live webcast of the session will be available on the ...

SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients ...